Download - Vaccine Candidates Paper
-
8/6/2019 Vaccine Candidates Paper
1/36
VACCINE CANDIDATES/MOLECULES
AGAINST MALARIA AND
TRYPANOSOMIASIS
-
8/6/2019 Vaccine Candidates Paper
2/36
TABLE OF CONTENTS
1. Introduction
2. Malaria
a. Overview
b. Malaria parasite development in human host
c. Mechanisms for potential vaccine action
d. Vaccine candidates/molecules against malaria
3. Trpanosomiasis
a. Overview
b. Trpanosomiasis parasite development in human host
c. Mechanisms for potential vaccine action
d. Vaccine candidates/molecules against trpanosomiasis
!. "onclusion
#. $eferences
~ 2~
-
8/6/2019 Vaccine Candidates Paper
3/36
INTRODUCTION
Malaria and Trpanosomiasis are two ma%or infectious diseases caused b
parasites of the phlum &roto'oa ( the proto'oans Plasmodium sp and
Trypanosoma sp. These parasites affect both human and animals) causing
severe) highl debilitating infections with resultant high mortalit and huge
economic losses recorded annuall. Various efforts have been deploed in the
control of these two diseases) including research into developing highl potent
vaccines for the prevention of these infections in human hosts. The efforts in
developing vaccines for these diseases have ielded a variet of vaccine
candidates from diverse sources with varing degrees of potential for success.
This paper does a review on the life ccle of the two causative agents of malaria
and trpanosomiasis) laing emphasis on the aspects of the mechanism of the
parasites* action in the human host that can be e+ploited for vaccine target
action. It then lists the various agents and molecules that have been identified as
potential candidates in the control of malaria and trpanosomiasis infections)
and gives an outline on the mechanisms of each and the e+tent of development
of each agent.
~ 3~
-
8/6/2019 Vaccine Candidates Paper
4/36
MALARIA
Overview
Malaria is a disease caused b several species of the intracellular proto'oan
parasite Plasmodium. The most popular species of this parasite that cause
infection in humans are Plasmodium malariae) P. vivax) P. ovale and P.
falciparum. Malaria is prevalent in tropical and sub,tropical regions of -frica)
-sia and outh,-merica) infecting 2# million people and resulting in between
one to three million deaths annuall 0now et al.) 2#. Transmission of this
disease is b the female form of the mosuito vector Anopheleswhich infects
the human host) while taing a blood meal) with sporo'oite stage parasites that
migrate to the liver and replicate rapidl to produce mero'oites that infect the
red blood cells in the blood stream and cause them to rupture) triggering off
clinical smptoms of the disease.
Immunit to malaria does occur naturall) but onl in response to repeated
infection with multiple strains. 04anert et al.) 25. In spite of its recogni'ed
virulence) repeated infection with malaria will result in gradual acuisition of
strain,specific) short,lived) antibod, and cell,mediated immunit to blood stage
malaria with prevention of6 first) complications and death) then disease and) in
~ 4~
-
8/6/2019 Vaccine Candidates Paper
5/36
areas of intense stable transmission) ultimatel suppression of parasitaemia to
low or undetectable levels 0Moorth and 7ill) 22. 7owever) the immunit
generated at an one stage of malaria is confined to that stage. Indeed) the
comple+ biolog of the Plasmodiumparasite and its wide antigenic diversit
has made the development of vaccine against malaria a huge challenge 08enton
and $eed) 29.
Malaria parasite development in human host
The life ccle of the malaria parasite Plasmodiumin the human host is split into
three stages ( the &re,erthroctic) :rthroctic and e+ual stages.
Pre-erythrocytic stage
This stage starts when the infective form of the malaria parasite( the sporo'oite
form ( is in%ected through the sin of a human host from the salivar glands of
the anopheline vector while the vector taes a blood meal. The sporo'oites
travel through the bloodstream to a relativel immune,protected environment
inside the liver cells of the host. 7ere) the develop for one to two wees)
undetected) without e+hibiting an smptoms or signs in the infected host. :ach
sporo'oite develops into thousands of mero'oites in the liver cell.
~ 5~
-
8/6/2019 Vaccine Candidates Paper
6/36
Erythrocytic stage
The mero'oites generated from the sporo'oites burst out of the liver) re,enter
the bloodstream and invade red blood cells) where the continue to replicate and
develop further into ring,shaped tropho'oites and se+ual forms of the parasite.
The mero'oites continue to rupture their host blood cells and reinvade other red
blood cells in ccles that last between 2! ( 92 hours) depending on the species
of the parasite.
Sexual stage
-fter roughl 1 das) the mero'oites in the $;"s begin to mature into se+ual
forms nown as microgametoctes and macrogametoctes. These gametoctes
are ingested b the mosuito vector during a blood meal and undergo
fertili'ation and development into sporo'oites within the vector) and the ccle
continues.
Mechanisms of potential vaccine action
-
8/6/2019 Vaccine Candidates Paper
7/36
each developmental stage involved in the life ccle ( each stage could have a
vaccine developed specificall to target the parasite.
Pre-erythrocytic stage vaccine action
- vaccine for this stage of the life ccle would be targeted against the
sporo'oite and the liver stages of the parasite. This vaccine could wor b either
blocing invasion of liver cells b sporo'oites 0antibod response or b
destroing infected liver cells 0cell,mediated response 0&rice and =ien) 21.
The possible antibod responses are thus blocing of hepatocte invasion and
illing of sporo'oites via complement fi+ation or opsonisation) and the possible
cell,mediated response 0Th1 response is the stimulation of " and " T,
cells) which are lmphoctes) to target and destro the infected liver cells
0
-
8/6/2019 Vaccine Candidates Paper
8/36
&rotein 0T$-& inPlasmodium falciparum( the corresponding protein found
onP. yoeliiis nown as poro'oite urface &rotein 2 0&2.
Erythrocytic stage vaccine action
- vaccine for this stage of the parasite life ccle would be directed against the
mero'oites stage of the parasite) and would be e+pected to inhibit either the
invasion of red blood cells b mero'oites or the multiplication of mero'oites in
the blood cells. This would be done b either agglutinating the mero'oites
before schi'ont rupture) or illing infected $;"s via opsonisation or
phagoctotic mechanisms) or agglutinating the infected $;"s and prevent
ctoadherence of $;" membrane proteins ( which causes smptomatic
reactions 0Moorth and 7ill) 22 ( b blocing receptor,ligand interactions.
The most popular antigen identified as a potential immune response generator at
this life ccle stage is the M&1 0Mero'oite urface &rotein 1 antigen. This
15#
-
8/6/2019 Vaccine Candidates Paper
9/36
0:$-) glcophorin binding protein 08;&,13) histidine rich protein 2 07$&,
2 and erthrocte membrane proteins 1 0&f:M&1.
Sexual stage vaccine action
The vaccine generated for this last stage of the parasite life ccle would be a
transmission,blocing vaccine ( one which induces an immune response in the
human host that will bloc the parasiteAs growth in the mosuito and
conseuentl bloc transmission of the parasite 0Miura et al.) 29. This would
be done b generating antibodies that would either neutrali'e the se+ual stages
i.e. the microgametoctes and macrogametoctes ( of Plasmodium in the
human host) destro the gametoctes ( either within the $;"s or along with
their $;" host) or interfere with the fertili'ation process of the parasite. This
vaccine is not aimed at giving protection to the person inoculated with it but at
preventing further spread of malaria in the host population. -ntigens which
have been identified as being capable of inducing these reactions include P.
falciparum surface protein antigens &fs 2# and &fs 2? and the P. vivax
homologues) referred to as &vs2# and 2? 0&rice and =ien) 21. These
proteins are members of the &2# famil of csteine,rich 2#
-
8/6/2019 Vaccine Candidates Paper
10/36
Vaccine candidates in the control of malaria
;ased on the various possible mechanisms for vaccine action in the control of
malaria listed above) some candidate agents/molecules have been identified and
developed. These candidate vaccines have been e+pressed and manufactured in
various was. Bntil the 15?s) all vaccines in use were live) attenuated or
inactivated whole organism vaccines mostl to viral pathogens 0Moorth and
7ill) 22. In recent times) the use of protein subunit vaccines) a product of
recombinant
-
8/6/2019 Vaccine Candidates Paper
11/36
-
8/6/2019 Vaccine Candidates Paper
12/36
studies in malaria e+posed populations 0Toure,;alde et al.) 25. It is being
tested in various formulations 0peptides) lipopeptides and
-
8/6/2019 Vaccine Candidates Paper
13/36
This was the ver first vaccine to undergo field trials. It was developed in
"olombia as a snthetic) multi,epitope) multistage peptide vaccine mi+ed with
alum as ad%uvant 0&atarroo et al.) 1552. The candidate presents a combination
of antigens from the sporo'oite 0using " repeats and mero'oite parasites. This
vaccine candidate had 9#E efficac rate during the &hase I trials and appeared
to be well tolerated b sub%ects and immunogenic. 7owever) the reported
efficac during the &hase III field trials was considered too low to warrant
further development 08alendo et al.) 2. The candidate was abandoned for a
while but is now being retested with new ad%uvants and is in the &hase I trial
0harma and &atha) 2?.
M&StDo ' (M&)t!-Sta*e DNA O+eat!on '
This is a multiple,antigen
-
8/6/2019 Vaccine Candidates Paper
14/36
candidate maes use of the whole organism , an attenuated form of the whole
parasite. @ive) attenuated parasites in the form of sporo'oites are harvested from
the salivar glands of irradiated mosuitoes) purified) and used as the basis for
vaccine formulation. anaria Inc. produces radiation,attenuated sporo'oites of
P. falciparumfrom infected mosuitoes in sufficient uantit and in a wa that
meets the regulator standards reuired for their use as a vaccine 0anaria MVI
&-T7 fact sheet. This has been achieved) and &hases I/IIa clinical trials have
begun using irradiation,attenuated sporo'oites delivered b intradermal or
subcutaneous in%ection 0Target and 8reenwood) 2?.
N.VAC-#$
This multistage vaccine candidate consists of genes from seven antigens from
different stages in the parasite life ccle ( "&) sporo'oite surface protein 2
0called &f&2) @-1) M&,1) :$-) -M-,1 and &fs2#. This candidate
ielded great results when tested first on rhesus mones6 ! out of the 9
antigens produced specific antibod responses 0"&) &f&2) M&1 and &4s2#
0Malaria site website. 7owever trials in humans did not ield impressive
results. Cevertheless) research has still been ongoing on this candidate.
MS#-1
This is one of the most popular vaccine candidate studies. -ntibodies to the ",
terminus of the M&,1 protein 0the !2 and 1?
-
8/6/2019 Vaccine Candidates Paper
15/36
to be associated with protection from high parasitaemia and clinical disease
0:gan et al.) 155F and have been shown to inhibit parasite growth and prevent
red cell invasion
0O*
-
8/6/2019 Vaccine Candidates Paper
16/36
SERA (#12% ant!*en
This vaccine candidate is the largest parasite protein. It accumulates in the
parasitophorous vacuole of tropho'oites and schi'onts and is processed into 3
fragments ( 1?
-
8/6/2019 Vaccine Candidates Paper
17/36
TBV2'-24
This vaccine candidate is a recombinant fusion protein of two ma%or
transmission,blocing antibodies , &fs2# and &fs2?. These antigens were
wored on at the CI7) B- as potential vaccines e+pressed as recombinant
protein secreted from Saccharomyces cerevisiae east 08o'ar et al.) 21.
Bnlie the other vaccine candidates) the efficac of a transmission,blocing
vaccine candidate is determined b an in,vitro membrane,feeding assa.
Immune sera generated in an animal is fed to parasite infected) laborator,raised
mosuitoes through a membrane. The mosuito gut can then be dissected to
determine the number of infectious gametoctes that developed. :ffective
transmission,blocing antibodies will prevent the development of the gametes
in the mosuito. 0Miura et al.) 29.
TR.#ANOSOMIASIS
Overview
Trpanosomiasis is a disease of both humans and animals that is e+pressed in
multiple forms based on species of parasite. There are three species that affect
humans ( Trypanosoma brucei gambiensis) which causes Dest -frican
trpanosomiasis) Trypanosoma brucei rhodensiensis) which causes :ast -frican
trpanosomiasis) and Trypanosoma crui) which causes -merican
~ 17~
-
8/6/2019 Vaccine Candidates Paper
18/36
trpanosomiasis) or "hagas disease. -frican trpanosomiasis currentl affects
#) people worldwide and is epidemic in 39 sub,aharan countries while
"hagas disease affects appro+imatel 2 million people in outh and "entral
-merica) Me+ico and the southern Bnited tates 0;hatia et al.) 2!.
Trpanosomiasis is transmitted b two insect vectors ( the tsetse fl 0!lossina
sp transmits the -frican trpanosomiasis and the triatomid bug 0Triatoma sp)
"hodniussp andPanstrongylus sp transmits "hagas disease. Infection of the
human host with -frican trpanosomiasis occurs when the infective stage ( the
metacclic stage ( is in%ected intradermall b the tsetse fl while it taes its
blood meal. These forms rapidl transform into blood,stage trpomastigotes)
and divide b binar fission in the interstitial spaces at the site of the bite
wound) resulting in the first indicative smptom of the infection ( a chancre.
Infection with -merican trpanosomiasis slightl differs from this mode in that
the infective stage ( the trpomastigote in this case ( is released in the faeces of
the triatomid bug) which it deposits near the site of the bite wound. These
trpomastigotes are then introduced into the human host through intact mucosal
membranes as the host rubs the faeces against their sin.
The Trypanosomaparasite possesses a speciali'ed mechanism that has enabled
it overcome the obstacles of the mammalian immune sstem b varing the
glcoproteins on its surface) and this phenomenon has made vaccine
development of this disease a ma%or challenge.
~ 18~
-
8/6/2019 Vaccine Candidates Paper
19/36
-
8/6/2019 Vaccine Candidates Paper
20/36
new infection sites. "linical manifestations usuall result from this infective
ccle. The bloodstream trpomastigotes do not replicate 0different from the
-frican trpanosomes. $eplication resumes when the parasites enter another
cell or are ingested b another vector.
Mechanisms for potential vaccine action
For a long time, the development of a vaccine against
trpanosomiasis ! in partic"lar #hagas disease ! $as impeded
d"e to the "ncertaint of the mechanisms involved in the
patholog of the disease %&"monteil, 2007'( )t $as not clear
$hether the tiss"e damage ca"sed * this disease $as a res"lt
of the presence and replication of intracell"lar amastigotes, or
ca"sed * the a"toimm"nit ind"ced * parasite antigens
mimic+ing host proteins, and th"s there $as conf"sion a*o"t
$hether to inhi*it the imm"ne sstem to red"ce a"toimm"nit,
or to stim"late it, to eliminate the parasite %&"monteil, 2007'(
)t is no$ accepted that the presence of parasites in cardiac
tiss"e is necessar to initiate and maintain the inammator
response, and that therape"tic treatments or vaccines aimed at
eliminating T. cruzi $o"ld facilitate the c"ring of the disease(
~ 20~
-
8/6/2019 Vaccine Candidates Paper
21/36
-here is a gro$ing consens"s that protection against T. cruzi
relies on a -h1 imm"ne response and the activation of
ctoto.ic #&8/- cells %artin and -arleton, 2004'( In a variet of
studies to identif the effector mechanisms reuired for the control of T. crui
infection) using animal models) components of the immune sstem lie
granuloctes) C= cells) " and " T,cell subsets and ltic antibodies
have shown potential as agents in the control of the disease 0Gacs et al.) 2#.
:fforts toward subunit vaccine development against T. crui have mainl
focused on antigens that are e+pressed on the plasma membrane of the parasite)
attached b a glcoslphosphatidlinositol 08&I anchor. 8&I proteins are
considered good antigenic targets because the are abundantl e+pressed in the
infective and intracellular stages of T. cru'i 0Gacs and 8arg) 2F and were
shown to be recogni'ed b both the humoral and cellular arms of the immune
sstem in infected hosts 0@ow et al.) 155?. 8&I proteins lie cru'ipain)
amastigote surface protein 1 and 2 0-&,1 and -&,2) trpomastigote surface
protein 1 0T-,1) and trans,sialidase 0T have been identified as potential
vaccine candidates in the control of trpanosomiasis. 7owever) these antigens
represent a limited repertoire of all the possible T. crui target molecules 0Teiel
et al.) 25.
~ 21~
-
8/6/2019 Vaccine Candidates Paper
22/36
Vaccine candidates in the control of trypanosomiasis
5S#6/7M#11
This vaccine candidate is a recombinant fusion protein comprised of
inetoplasmid membrane protein =M&11) a protein associated with the
lpophosphoglcan molecule in T. crui) and 7&9) a gene also e+pressed in
T. crui. =M&11 is located mainl in the parasite*s flagellar pocet and is
associated with ctoseletal structures responsible for the mobilit of the
parasite and its attachment to the host cell 0Thomas et al.) 2. Hensen et al.
0155? reported this candidate to be a potent inducer of immune response) and
when it was tested in murine model b &lanelles et al. 021) it was found to
generate long,lasting humoral immune response against =M&11 protein and
activate " ctoto+ic lmphoctes.
C&8!+a!n
"ru'ipain is the ma%or csteinl proteinase of Trypanosoma crui. It has been
demonstrated to be immunogenic in both man and mice. In a stud b chnapp
et al. 022) immuni'ation of mice with
-
8/6/2019 Vaccine Candidates Paper
23/36
conversion of the parasite from the complement,sensitive insect,stage
epimastigote to the complement,resistant bloodstream,stage trpomastigote.
0Corris) chrimpf and 'abo) 1559. The vaccine candidate is a recombinant
vaccine derived from anE. colie+pression sstem and a plasmid encoding the
full,length crpstructural gene using an euarotic promoter. This candidate was
tested in a murine model b epulveda et al.02 and was shown to generate
Th1 tpe T,cell response.
9-Ga)acto:;)cea0!de
,8alactoslceramide is a specific ligand for activation of Catural =iller 0C=
T,cells. C= T,cells have the capacit to secrete large amounts of ctoines and
effectivel e+ert protective immune responses against infectious diseases
0mth et al.) 22. The also have the potential to accelerate the induction
and maintenance of effective " T,cell responses 0"arvalho et al.) 22
through the gamma interferon 0I4C,9 and interleuin,! 0I@,! ctoines the
secrete.
-
8/6/2019 Vaccine Candidates Paper
24/36
The Tc#2 protein of Trypanosoma crui belongs to the thiol,disulfide
o+idoreductase famil) and is crucial for parasite survival and virulence) as it
e+erts immunoregulator functions. In vitro) Tc#2 in combination with I4C,
activates human macrophages) and in vivo it relieves the immunosuppression
associated with acute infection and elicits specific immune response 0Ouaissi et
al.) 22. This candidate was tested in mice as a pc
-
8/6/2019 Vaccine Candidates Paper
25/36
its immunogenic portions 04u%imura et al.) 21. It was discovered that the
gene portions capable of generating both " Th1 and " Tc1 cells
produced the most effective responses. The T-,1 protein was developed as
two
-
8/6/2019 Vaccine Candidates Paper
26/36
potential antigens. Dith the implementation of these advances) it is hoped that
viable vaccines would be developed for these diseases in the not too distant
future.
REFERENCES
B
-
8/6/2019 Vaccine Candidates Paper
27/36
Cava)
T,cell responses against malaria liver stages.$atural
%edicine4@1FF,19.
Da&e:!e:, #, TO))o0o, B, Ben Mo
-
8/6/2019 Vaccine Candidates Paper
28/36
E)-Sa and " T,"ell :pitopes
-re Important for :fficient &rotective Immunit Induced b ~ 28~
-
8/6/2019 Vaccine Candidates Paper
29/36
-
8/6/2019 Vaccine Candidates Paper
30/36
5o)de, A A, B)ac0an, M ?, B&*
protein 1 0msp,1015 and T helper epitopes of tetanus to+oid. accine146
#31'5
Lo, 5 #, Santo:, M A, !8e), B and Ta)eton, R L (1334 -mastigote
surface proteins of Trypanosoma cruiare targets for " "T@.(ournal
of #mmunology1%661?19,1?23
Mat!n, D and Ta)eton, R (266>8eneration) specificit) and function of
" T cells in Trypanosoma crui infection. #mmunological "evie0s
261(16 3!(319
~ 30~
-
8/6/2019 Vaccine Candidates Paper
31/36
M!;a
S, Tae&c
-
8/6/2019 Vaccine Candidates Paper
32/36
No!:, 7 A, Sc
Via Toll,@ie $eceptor 2) and "onfers &rotection -gainst @ethal Infection.
The (ournal of #mmunology1%4@F3FF,F39!
#an, , 5&an*, D,
-
8/6/2019 Vaccine Candidates Paper
33/36
enhances product ield) immunogenicit) and antibod,mediated inhibition
of parasite growth in vitro.(ournal of #mmunology12(166 F1F9,9!
#ae, S E, Monte!t
-
8/6/2019 Vaccine Candidates Paper
34/36
protection against Trypanosoma crui infection. #nfection and #mmunity
%4(36 !5?F,!551
S
-
8/6/2019 Vaccine Candidates Paper
35/36
Ta*ett, G and Geenood, B M (2664 Malaria vaccines and their
potential role in the elimination of malaria. %alaria (ournal (S&++) 16
1
Te!e), V, A)a-Soto, C D, Gon8J)e8 Ca++a, S M, #o:tan, M and
SJnc
-
8/6/2019 Vaccine Candidates Paper
36/36
Vaccination with 8enes :ncoding the -mastigote urface &rotein,2 and
Trans,ialidase.1uman !ene Therapy1'6 ?9?,??F
!8e), B, Ga*, N and Ta)eton, R L (1334 Vaccination with
Trpomastigote urface -ntigen 1,:ncoding &lasmid